The treatment, a type of immunotherapy which harnesses the body’s immune system to fight cancer, was found to shrink tumours ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

The new drug, known as VIR-5500, uses a so-called cloaking device and only activates when it reaches the tumour ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have advanced, ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A “search and destroy” treatment has been found to halt tumours in some men with incurable prostate cancer. The early-stage ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

Prostate and skin cancers are among the most common cancers affecting men. In Advanced Prostate Cancer, lifelong treatment modalities are making a difference, challenges remain for patients with high ...